Galantamine in the treatment of moderate-to-advanced Alzheimer's patients: Clinical outcomes in assisted living

被引：0
|
作者：
Shua-Haim, J
Pass, M
Patel, S
Patel, S
机构：
来源：
GERONTOLOGIST | 2003年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学]; R592 [老年病学];
学科分类号：
1002 ; 100203 ; 100602 ;
摘要：
引用
收藏
页码：433 / 433
页数：1
相关论文
共 50 条
  • [21] Multidisciplinary intensive outpatient rehabilitation program for patients with moderate-to-advanced Parkinson's disease
    Cohen, Noa
    Manor, Yael
    Green, Yitzhak
    Tahel, Gail
    Badichi, Inbal
    Ben-Or, Galit
    Shtainshlaifer, Neta
    Shiffer, Asaf
    Gabso-Rajuan, Maayan
    Kurtzman, Hadar
    Shtraifler, Liat
    Furst, Tova
    Shtein, Shlomi
    Shulman, Juli
    Hyute, Anat
    Levin, Issachar
    Inbar, Noit
    Ariela, Hilel
    Peled, Roni
    Gheriani, Nurit
    Ezra, Adi
    Messer, Stav
    Geva, Noya
    Giladi, Nir
    Gurevich, Tanya
    NEUROREHABILITATION, 2021, 49 (01) : 47 - 55
  • [22] Long-term outcomes of galantamine treatment in patients with Alzheimer disease
    Lyketsos, CG
    Reichman, WE
    Kershaw, P
    Zhu, Y
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 12 (05): : 473 - 482
  • [23] Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE≤12) for up to six months
    Wilkinson, DG
    Hock, C
    Farlow, M
    Van Baelen, B
    Schwalen, S
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (07) : 509 - 514
  • [24] Galantamine in the treatment of Alzheimer's disease
    Latalova, K. L.
    Pidrman, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S476 - S476
  • [25] The safety of combined galantamine-memantine treatment in mild to moderate Alzheimer's disease
    Ramaswamy, K.
    Amatniek, J.
    Crivera, C.
    Rupnow, M.
    Zhu, Y.
    Hammond, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 68 - 68
  • [26] Safety of galantamine and memantine in combination usage in the treatment of mild to moderate Alzheimer's disease
    Ramaswamy, K
    Amatniek, J
    Zhu, Y
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S298 - S298
  • [27] Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease
    Brodaty, H
    Corey-Bloom, J
    Potocnik, FCV
    Truyen, L
    Gold, M
    Damaraju, CRV
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2005, 20 (2-3) : 120 - 132
  • [28] Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States
    Migliaccio-Walle, K
    Getsios, D
    Caro, JJ
    Ishak, KJ
    O'Brien, JA
    Papadopoulos, G
    CLINICAL THERAPEUTICS, 2003, 25 (06) : 1806 - 1825
  • [29] Safety and effectiveness of galantamine for mild to moderate Alzheimer's disease
    Alvarez, F. J.
    Blesa, R.
    Ezpeleta, D.
    Romo, I.
    Garcia-Ribas, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 73 - 73
  • [30] Economic impact of galantamine in mild to moderate Alzheimer's disease
    Caro, J
    Migliaccio-Walle, K
    Ishak, KJ
    Getsios, D
    O'Brien, JA
    Papadopoulos, G
    ANNALS OF NEUROLOGY, 2001, 50 (03) : S79 - S79
12345